Trial
NCT05951205
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Vertex Pharmaceuticals Incorporated
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Exa-cel
Why stopped
Modification to the clinical development plan
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-25